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Abstract
Background: Evidence indicates that dietary fats and physical activity influence bone health. The purpose of this
study was to examine the effects of long-term aerobic exercise and omega-3 (N-3) supplementation on serum
inflammatory markers, bone mineral density (BMD), and bone biomarkers in post-menopausal women.
Methods: Seventy-nine healthy sedentary post-menopausal women aged 58-78 years participated in this study.
Subjects were randomized to one of 4 groups: exercise + supplement (E+S, n = 21), exercise (E, n = 20),
supplement (S, n = 20), and control (Con, n = 18) groups. The subjects in the E+S and E groups performed aerobic
exercise training (walking and jogging) up to 65% of HRmax, three times a week for 24 weeks. Subjects in the E+S
and S groups consumed 1000 mg/d N-3 for 24 weeks. The lumbar spine (L2-L4) and femoral neck BMD, serum
tumor necrosis factor (TNF) a, interleukin (IL) 6, prostaglandin (PG) E2, estrogen, osteocalcin, 1, 25-dihydroxyvitamin
D3 (1, 25 Vit D), C-telopeptide (CTX), parathyroid hormone (PTH) and calcitonin (CT) were measured at baseline, the
end of week 12 and 24.
Results: Serum estrogen, osteocalcin, 1, 25 Vit D, CT, L2-L4 and femoral neck BMD measures increased (P < 0.05)
and the serum CTX, PTH, TNF-a, IL-6, and PGE2 decreased (P < 0.05) in E + S group after the 24 wk intervention
but not in the E or S intervention groups. L2-L4 and femoral neck BMD, estrogen, osteocalcin, and CT were
negatively (P < 0.05) correlated with TNF-a and PGE2. PTH and CT were correlated positively and negatively with
IL-6, respectively (P < 0.05).
Conclusions: The present study demonstrates that long-term aerobic exercise training plus N-3 supplementation
have a synergistic effect in attenuating inflammation and augmenting BMD in post-menopausal osteoporosis.
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Background
With an aging society, osteoporosis has a profound eco-
nomic impact [1], and primarily affects postmenopausal
women. The estrogen deficiency accompanying meno-
pause induces bone loss [2], with an abrupt decline after
menopause. Prophylactic interventions to suppress this
decline in bone mineral density (BMD) after menopause
are needed [1].
Several lines of evidence indicate that inflammation may
contribute to the disorder of osteoporosis [3-5]. Among
older women, higher concentrations of inflammatory
markers have been associated with an increased risk of
incident fracture [6]. Pro-inflammatory cytokines, which
are critical mediators of inflammatory responses, have also
been found to regulate bone metabolism, even in indivi-
duals without immunological diseases [7]. Interleukin (IL)
6, has been shown to promote osteoclast differentiation
and activation [8], while tumor necrosis factor (TNF) a,
has been shown to stimulate bone resorption and to inhi-
bit bone formation [9]. Prostaglandins (PGs), especially
* Correspondence: hajizadeh.sci.phys@gmail.com
2Department of Exercise Physiology, Faculty of Physical Education and Sport
Science, Urmia University, Urmia, Iran
Full list of author information is available at the end of the article
Tartibian et al. Nutrition & Metabolism 2011, 8:71
http://www.nutritionandmetabolism.com/content/8/1/71
© 2011 Tartibian et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.PGE2, are also known to be potent activators of bone
remodeling [10,11].
Evidence indicates that dietary fats can also influence
bone health [12]. In particular, the omega-3 (N-3) poly-
unsaturated fatty acids (PUFAs) may be beneficial, as
they have been shown to inhibit osteoclast activity and
enhance osteoblast activity in animals [13]. Optimal
quantities of N-3 PUFAs, thus, appear to inhibit bone
resorption and promote bone formation. One study has
shown that twelve months of eicosapentaenoic acid
(EPA) supplementation increases BMD in post-meno-
pausal women [14]. Beneficial effects of N-3 PUFAs on
markers of bone resorption and formation [15-17], as
well as on inflammatory markers such as TNF-a,I L - 1 b,
IL-6, and PGE2 in animal and human studies [18], have
also been reported. Our laboratory recently investigated
the effects of ingestion of N-3 PUFA and aerobic exercise
intervention on the calcium regulating hormones but not
on BMD in healthy post-menopausal women. These
results indicated that consuming 1000 mg·day
-1 of N-3
PUFA during 16 weeks of moderate intensity weight-
bearing exercise training significantly increased CT and
estrogen levels and decreased PTH levels [12].
In addition, physical activity plays an important role in
the prevention of osteoporosis via development as well as
maintenance of BMD [2,19]. It is commonly accepted that
participation in exercise provides an osteogenic stimulus
to the bones [20], by increasing serum concentrations of
bone formation markers [12,21-26] as well as decreasing
bone resorption markers [12,21,25-30]. Likewise moderate
intensity aerobic exercise has also been shown to attenuate
the serum markers of inflammation in post-menopausal
and older women [31]. Recently a 10 month randomized
trial aerobic exercise training showed reduced C-reactive
protein (CRP), IL-6, and IL-18 concentrations among
older men and women [32]. These changes in inflamma-
tory indices may contribute significantly to the inverse
relationship between physical activity and osteoporosis.
Considering the well-known anti-inflammatory effects of
exercise training [31-33], N-3 PUFAs [18], and the strong
association between inflammatory markers and meno-
pause-related osteoporosis [3-6], we hypothesized that the
exercise training as well as N-3 PUFA supplementation
would be effective in reducing chronic inflammation in
post-menopausal women, and those changes in circulating
inflammatory markers would be related to improvements
in osteoporosis control. Thus, the purposes of this study
were to determine whether 1) moderate intensity aerobic
exercise training plus N-3 PUFA supplementation
are effective in reducing serum concentrations of inflam-
matory markers IL-6, TNF-a,a n dP G E 2, 2) moderate
intensity aerobic exercise training plus N-3 PUFA supple-
mentation are effective at improving BMD, and suppres-
sing bone resorption; and 3) changes in inflammatory
markers are associated with changes in BMD biomarkers
following 24 weeks of aerobic exercise and N-3 PUFA sup-
plementation in post-menopausal women.
Materials and methods
Experimental Design and Subjects
Seventy-nine post-menopausal women (aged 58-78)
volunteered and gave written consent for this study
which was approved by the Human Studies Committee
of Urmia University, IRAN. Subjects had bone density
(lumbar spine (L2-L4) and femoral neck BMD), inflam-
matory markers (TNF-a,I L - 6 ,P G E 2), hormone concen-
trations (estrogen, osteocalcin, 1, 25 Vit D, CTX, PTH,
CT), blood ions (Ca
2+, phosphorus, and fatty acid com-
position of neutrophil extracts) measured at baseline, the
end of week 12 (after 24 hours of recovery), and the end
of week 24 (after 24 hours of recovery).
The women were sedentary, in good health, at least 8
years past-menopause, and taking no medications. Preli-
minary screening included a medical history, physical
examination, and a Bruce treadmill test [34]. Subjects
were randomly assigned to one of 4 groups: exercise +
supplement (E+S, n = 21), exercise only (E, n = 20), sup-
plement only (S, n = 20), and control (Con, n = 18)
groups. Leisure, household, and occupational activity was
estimated with the Physical Activity Scale for the Elderly
Questionnaire [35] (Table 1).
Oral omega-3
The E+S and S groups were supplemented with N-3 PUFA
capsules (Viva Omega-3 fish oil, Manufactured by: Viva
Pharmaceutical Inc, Richmond B.C. V6V 1K8, Canada),
containing 180 mg EPA and 120 mg Docosahexaenoic acid
(DHA), to supply a total of 1000 mg/day [12] of N-3
PUFAs over 24 weeks. The degree of compliance with N-3
PUFA supplements, as determined by pill counts, was 96 ±
9%. Also, the incorporation of EPA and DHA into the cell
membranes of neutrophils was measured. Information was
collected from each individual by trained interviewers in
face to face interviews based on a structured and previously
validated questionnaire that included the following: socio-
demographic data; years since menopause; physical activ-
ities, including hours spent sitting, standing, walking,
sports, and leisure activities; medications; smoking and
drinking alcohol; and other factors that may have possible
confounding effects on N-3 PUFA consumption and meta-
bolism of bone and lipid [36].
All subjects were requested to consume their usual
diet throughout the period of study. A detailed diary of
all types and household measures of food and drinks
consumed, including brand names, was kept for base-
line, week 12 and week 24 [37]. Dietary intakes did not
alter more than would be expected over the 24 weeks of
the study (Table 2). Daily intakes of calcium, vitamin D,
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Variables Groups E + S (n = 21) E (n = 20) S (n = 20) Con (n = 18) P <
Age (yr) 59.7 ± 2.3 61.4 ± 6.9 63.1 ± 7.5 58.9 ± 8.1 0.604
Height (m) 1.64 ± 0.14 1.67 ± 0.08 1.69 ± 0.09 1.68 ± 0.16 .6410
Weight (kg) 75.2 ± 12.2 77.5 ± 10.4 78.3 ± 16.1 75.9 ± 17.2 .8150
BMI (kg·m
-2) 26.3 ± 4.8 25.1 ± 7.1 27.9 ± 5.4 28.5 ± 3.7 .7700
Fat (%) 29.8 ± 5.8 27.9 ± 7.5 29.1 ± 7.2 28.1 ± 6.8 .8050
VO2max 33.7 ± 4.9 32.2 ± 3.1 31.2 ± 4.5 32.7 ± 4.4 .0660
PAS 135 ± 60 134 ± 51 140 ± 69 138 ± 61 .7010




Physical activity score. Values are mean ± SD
Table 2 Differences in dietary intakes for the women
Daily intakes Groups E + S E S Con P <
Total energy (kcal)
Before 2116 ± 371 2101 ± 358 2121 ± 360 2099 ± 381 0.149
After † 2207 ± 354 † 2211 ± 344 2119 ± 369 2109 ± 364 0.074
Proteins (g)
Before 81 ± 14 77 ± 21 82 ± 17 80 ± 20 0.198
After 78 ± 19 81 ± 10 79 ± 18 82 ± 12 0.357
Carbohydrates (g)
Before 224 ± 59 218 ± 51 230 ± 58 228 ± 65 0.091
After 230 ± 66 225 ± 55 233 ± 49 227 ± 60 0.208
Lipids (g)
Before 74 ± 12 69 ± 24 71 ± 29 73 ± 22 0.077
After 72 ± 22 74 ± 18 68 ± 23 71 ± 12 0.201
SFA (g)
Before 24 ± 9 23 ± 6 22 ± 5 22 ± 8 0.087
After 23 ± 5 23 ± 8 23 ± 7 22 ± 5 0.141
MUFA (g)
Before 26 ± 7 28 ± 5 27 ± 6 29 ± 9 0.536
After 27 ± 5 28 ± 9 27 ± 8 28 ± 6 0.339
PUFA (g)
Before 12 ± 4 11 ± 7 11 ± 6 11 ± 9 0.067
After 11 ± 9 11 ± 8 11 ± 8 11 ± 6 0.094
Total fibers (g)
Before 18 ± 9 17 ± 8 17 ± 5 18 ± 6 0.091
After 17 ± 8 18 ± 6 17 ± 9 18 ± 8 0.082
Calcium (mg)
Before 690.4 ± 234.7 692.3 ± 244.9 694.5 ± 227.3 687.6 ± 189.9 0.092
After 694.1 ± 212.1 692.8 ± 259.1 693.4 ± 235.2 690.2 ± 204.8 0.421
Vitamin D (μg)
Before 9.7 ± 6.5 9.6 ± 6.3 9.8 ± 6.9 9.4 ± 5.7 0.114
After 9.6 ± 6.8 9.7 ± 6.8 9.4 ± 6.5 9.7 ± 7.1 0.067
Vitamin K (μg)
Before 435.1 ± 211.7 431.9 ± 191.2 436.2 ± 204.7 434.5 ± 197.1 0.336
After 433.8 ± 227.2 435.1 ± 201.7 433.9 ± 211.1 436.2 ± 217.4 0.081
E+S = Exercise + Supplement; E = Exercise; S = Supplement; Con = Control; BMI = Body mass index; SFA = Saturated fatty acid; MUFA = Monounsaturated fatty
acid; PUFA = Polyunsaturated fatty acid
† P < 0.05, significantly different from baseline values (within groups, baseline vs. week 24).
Values are mean ± SD
Tartibian et al. Nutrition & Metabolism 2011, 8:71
http://www.nutritionandmetabolism.com/content/8/1/71
Page 3 of 13carbohydrates, lipids, saturated fatty acid, mono-unsatu-
rated fatty acid, PUFA, proteins and total energy were
calculated from the daily record by the dietitian on the
basis of the fifth revision of the standard tables of food
composition in Japan [36]. Information on use of medi-
cations and drugs was also obtained through standard
and self-reported questionnaires in accordance to the
researchers’ recommendations [12].
Exercise program
In the first 12 weeks of the study, subjects in E+S and E
groups walked or jogged on a treadmill 25-30 min·day
-1,
3-4 days·week
-1, at 45-55% of their individually deter-
mined HRmax. As their exercise tolerance improved, the
intensity and duration of exercise training in the second
12 weeks of the study were increased to 40-45 min·day
-1,
4-6 days·week
-1; at an intensity of 55-65% of HRmax.
Adherence to the exercise prescription was documented
through the use of Polar heart rate monitors, and sub-
jects received feedback if training intensities were either
too high or low in comparison with desirable intensities.
Attendance was taken at each exercise session to monitor
compliance with the program. Subjects were contacted if
an exercise session was missed. In those women who
completed the interventions, there was > 95% compliance
for attendance at the exercise sessions. Nine subjects (E +
S group, n = 1; E group, n = 2; S group, n = 2; Con group,
n = 4) could not complete the study protocol and were
excluded from the study. All exercise sessions began
between 0600 and 0800 h. The S and Con group subjects
were instructed to maintain their current physical activity
levels during the study [12].
Measurements
Blood sampling and assays
Following a 12-hour overnight fast, blood samples were
taken between 0700-0800 h and collected from an antecu-
bital vein. Samples were taken at baseline, 12 and 24 wks.
Standard procedures for blood handling and processing
were followed. All samples were taken 24 h after the last
exercise bout. Blood samples were analyzed for serum
TNF-a, IL-6, PGE2, estrogen, osteocalcin, 1, 25- Vit D,
CTX, PTH, CT, Ca
2+, phosphorus, and fatty acid composi-
tion of neutrophil extracts.
Serum IL-6 and TNF-a measurements were assayed
using an enzyme-linked immunosorbent assay (ELISA) kit
from Biosource (Nivelles, Belgium). PGE2 was determined
using competitive enzyme immunoassay (PGE2 EIA kit-
Monoclonal [solid plate], Ceyman-Germany). Serum
estrogen levels were detected through a chemiluminescent
method (Roche Diagnostics, Indianapolis, IN, USA) using
an automatic immunoanalyzer. Circulating osteocalcin
was measured using a previously developed radioimmu-
noassay (RIA). Serum 1, 25- Vit D was measured by a
radioreceptor assay. Serum CTX was assessed using
Serum Cross Laps One-Step ELISA (Osteometer BioTech,
Herlev, Denmark). Serum PTH levels were measured
through an electrochemiluminescent method, using
Elecsys Systems/Modular analytics E170 (catalog number,
11972103; Roche Diagnostics). CT was determined by
radioimmunoassay (RIA) with a polyclonal antiserum
directed against the carboxyterminus. The antibodies were
produced in rabbits against human CT, using a calcitonin
kit (CIS Bio International ORIS groups, France). Serum
calcium and phosphorus levels were measured by standard
automated laboratory techniques. Incorporation of EPA
and DHA into the cell membranes of neutrophils was ana-
lyzed using gas chromatography using known standards
[12,37].
Bone measurements
BMD measurements were made at the anterior-posterior
lumbar spine (L2-L4) and the non-dominant proximal
femur, including femoral neck, using dual-energy X-ray
absorptiometry (DXA; Norland XR36; Norland, Fort Atkin-
son, WI, USA). The coefficients of variation (CV) for the
L2-L4 and femoral neck were 1.21% and 1.54% respectively.
Statistical analysis
Group differences were determined using a one way ana-
lysis of variance (ANOVA) for repeated measures, for
continuous variables. If the main effects F-ratio was sig-
nificant, differences among groups were subsequently
identified using a Bonferroni post-hoc analysis. Partial
correlation and mixed model regression coefficients were
used to evaluate the association between the variables
studied. The statistical software program SPSS (SPSS Co,
Chicago IL, version 17) for windows was used for data
analysis. All statistical tests were performed and consid-
ered significant at a P ≤ 0.05.
Results
Baseline characteristics of the four study groups did not
show any significant differences among groups in L2-L4
and femoral neck BMD, TNF-a, IL-6, PGE2,e s t r o g e n ,
osteocalcin, 1, 25 Vit D, CTX, PTH, CT, Ca
2+,a n d
phosphorus (P > 0.05) (Table 3).
Bone measurements
At 12 wks of the intervention, L2-L4 BMD was not signifi-
cantly different than baseline values and there were no dif-
ference between group values (Table 3). However by 24
wks, the E+S intervention resulted in a significant increase
in L2-L4 BMD from the baseline value (0.17 ± 0.15 g/cm
2
increase, P < 0.05). Although there were slight increases in
L2-L4 BMD in the E and S groups, it was not significant
and these changes were smaller (P < 0.05) than seen in the
E+S group, but greater than seen in the control group (P <
0.05). Likewise the femoral neck BMD also increased in
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Biomarkers in Different Groups of Post-Menopausal Women
Variables Groups S+E E S Con *P<
L2-L4 BMD (g/cm
2)
Baseline 0.79 ± 0.12 0.79 ± 0.12 0.78 ± 0.12 0.79 ± 0.14 0.995
Week 12 0.84 ± 0.14 0.81 ± 0.12 0.79 ± 0.11 0.79 ± 0.13 0.51
CfB 0.05 ± 0.15 0.02 ± 0.06 0.01 ± 0.09 -0.01 ± 0.06
(%) 3.3 (0, 15.6) 0.7 (-1.3, 7.5) 0 (-1, 10) 0 (0, 0)
Week 24 0.91 ± 0.07
2, 3, 4 †# 0.84 ± 0.13
1, 4 0.83 ± 0.1
1, 4 0.73 ± 0.14
1, 2, 3 †# *0.001
CfB 0.13 ± 0.15 0.05 ± 0.14 0.05 ± 0.13 -0.06 ± 0.16
(%) 15.8 (3.3, 42.5) 7.6 (0, 19.9) 1.5 (-0.2, 18) -8.5 (-23.9, 0)
Femoral neck BMD (g/cm
2)
Baseline 0.68 ± 0.11 0.67 ± 0.10 0.67 ± 0.10 0.69 ± 0.08 0.981
Week 12 0.78 ± 0.17
2, 3, 4 † 0.71 ± 0.15
4 0.71 ± 0.09
1, 4 0.65 ± 0.07
1, 2, 3 *0.013
CfB 0.11 ± 0.21 0.03 ± 0.21 0.03 ± 0.07 -0.04 ± 0.06
(%) 17.9 (-10.6, 48.9) 3.6 (-12.2, 21.2) 1.9 (0, 6.7) -2.8 (-5.9, -1.4)
Week 24 0. 87 ± 0.17
2, 3, 4 †# 0.74 ± 0.13
1, 4 0.74 ± 0.15
1, 4 0.63 ± 0.09
1, 2, 3 *0.001
CfB 0.19 ± 0.18 0.07 ± 0.19 0.07 ± 0.13 -0.06 ± 0.1
(%) 19.3 (-2.5, 56.8) 8 (-11.2, 22.9) 17 (-3.4, 25.3) -7.5 (-11.4, -0.3)
TNF-a (pg/ml)
Baseline 79 ± 15.4 77.6 ± 17.1 76.6 ± 17.3 79.8 ± 8.3 0.943
Week 12 44.9 ± 20.3
2, 3, 4† 68.5 ± 16.9
1, 4 61.1 ± 24.2
1, 4† 83.6 ± 8.6
1, 2, 3 *0.001
CfB -34.1 ± 24.7 -9.2 ± 29.3 -16.9 ± 33.1 3.8 ± 6.7
(%) -47 (-55.7, -33.8) -22.1 (-27.2, 9.3) -27.4 (-50.9, -2.3) 5.4 (0, 12.4)
Week 24 19.7 ± 17.4
2, 3, 4†# 58.2 ± 28.1
1, 3, 4 34 ± 31.8
1, 2, 4†# 88.3 ± 20.6
1, 2, 3 *0.001
CfB -59.3 ± 23.7 -19.4 ± 31.9 -42.5 ± 30.8 8.5 ± 17.9
(%) -81.7 (-85.6, -78.4) -16.1 (-64.1, 8.9) -76.9 (-83.5, -10) 8.8 (0.5, 17.1)
IL-6 (pg/ml)
Baseline 49.3 ± 26.5 50.7 ± 25.1 48.8 ± 27.2 51.6 ± 20.5 0.991
Week 12 40.2 ± 17.3 49.6 ± 30.9 46.4 ± 29.9 54.6 ± 29.2 0.547
CfB -9.1 ± 14.8 -1.1 ± 37.8 -2.4 ± 31.1 3.1 ± 31.3
(%) -11.2 (-24.2, 12.2) -0.4 (-49.3, 72.4) 0.1 (-39.6, 21.6) -13.5 (-37.9, 66.3)
Week 24 21.9 ± 10
2, 3, 4†# 43 ± 26.5
1, 4 40.8 ± 26.6
1, 4 63 ± 30.3
1, 2, 3 *0.001
CfB -27.4 ± 29.7 -7.7 ± 48.3 -8 ± 24.2 11.4 ± 37.9
(%) -40.8 (-76.4, -31.4) -37.8 (-70.1, 155.6) -24.5 (-40.7, 3) 20.1 (-39.8, 120)
PGE2 (pg/ml)
Baseline 16.2 ± 4.9 16.6 ± 5.7 16.6 ± 5.9 16.1 ± 5.3 0.991
Week 12 11.2 ± 4.2
3, 4† 12.8 ± 4.9
3, 4 15.1 ± 2.7
1, 2 17.6 ± 2.8
1, 2 *0.001
CfB -5 ± 6.1 -3.8 ± 6.6 -1.6 ± 7.4 1.6 ± 5
(%) -27.5 (-53.1, 10) -7.4 (-29.2, 0) -7 (-35.4, 26.6) 3.4 (-10.3, 47.3)
Week 24 4.6 ± 2.3
2, 3, 4†# 11.3 ± 4.1
1, 4 † 12.6 ± 3
1, 4 † 17.3 ± 2.7
1, 2, 3 *0.001
CfB -11.5 ± 5.9 -5.3 ± 8.4 -4 ± 7.4 1.2 ± 5.4
(%) -69.9 (-80.1, -65) -29.7 (-58.5, -2.8) -32 (-51.4, 15.4) 6 (-17.5, 43.2)
Estrogen (pg/ml)
Baseline 15 ± 7.4 15.6 ± 8.1 15.8 ± 8 14.8 ± 8.5 0.983
Week 12 24 ± 7.1
2, 3, 4† 17 ± 7.7
1, 4 18.6 ± 6
1, 4 12.7 ± 7.4
1, 2, 3 *0.001
CfB 8.9 ± 11 1.4 ± 11.1 2.7 ± 10.4 -2.1 ± 13
(%) 65.9 (40.7, 134.2) -14.4 (-36.9, 96.7) -1.7 (-26, 127.5) 1.4 (-45.8, 35.2)
Week 24 33.7 ± 11.9
2, 3, 4†# 20.2 ± 7.4
1, 4 21.4 ± 8.1
1, 4 12.9 ± 8.5
1, 2, 3 *0.001
CfB 18.7 ± 11.6 4.6 ± 10.4 5.5 ± 10.2 -1.8 ± 8.8
(%) 126.6 (50, 215) 52.8 (-8.8, 102.4) 56 (-24.2, 108) 0 (0, 0)
Osteocalcin (ng/ml)
Baseline 26.3 ± 8.7 25.8 ± 8.4 26.7 ± 8.6 24.4 ± 7.7 0.891
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kers in Different Groups of Post-Menopausal Women (Continued)
Week 12 34.4 ± 8.4
4† 27.2 ± 8.7 28.5 ± 10.1 23.6 ± 8.2
1 *0.016
CfB 8.1 ± 12.2 1.4 ± 12.1 1.8 ± 14.7 -0.8 ± 11
(%) 37.8 (-13.4, 83.4) 6.7 (-19.9, 55.2) -2.4 (-34.7, 27.8) 0 (-13.5, 27.4)
Week 24 39.2 ± 8.7
2, 3, 4† 29.8 ± 10.5
1 28.1 ± 9.6
1 22.6 ± 7.3
1 *0.001
CfB 12.9 ± 14.7 4 ± 12.9 1.4 ± 15.1 -1.8 ± 7.6
(%) 89.1 (9.9, 131.1) 4.6 (-21.7, 67) 15.1 (-30.9, 74.4) 0 (-7.7, 0)
1, 25 Vit D (pg/ml)
Baseline 39.9 ± 19.1 41.5 ± 21.9 39.3 ± 17.2 42.3 ± 20.6 0.974
Week 12 50 ± 19.1 † 44.6 ± 17.9 45.4 ± 19.8 41.4 ± 15.7 0.648
CfB 10.1 ± 28.7 3 ± 30.4 6.1 ± 24.7 -1 ± 25.1
(%) 15.1 (-8.4, 132.5) -28.3 (-39, 146.5) 32.7 (-33.6, 103.2) -11.7 (-34.7, 84.5)
Week 24 66.9 ± 14.3
2, 3, 4†# 54.9 ± 23.1
1, 4 49.4 ± 19.1
1, 4 38 ± 19.9
1, 2, 3 *0.007
CfB 26 ± 23 13.4 ± 26.1 7.2 ± 28.5 -4.3 ± 32.8
(%) 62.4 (4, 204.6) 53 (6.8, 76.7) 44.9 (-34.7, 103.2) -9.2 (-53.5, 62.1)
CTX (ng/ml)
Baseline 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.988
Week 12 0.4 ± 0.1 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.635
CfB -0.1 ± 0.2 0 ± 0.2 0 ± 0.2 0 ± 0.2
(%) -6.3 (-18.8, 24) -21.7 (-44.2, 47.7) 0 (-25.3, 20.1) -3.7 (-27.5, 42.8)
Week 24 0.3 ± 0.1
4† 0.4 ± 0.1 0.5 ± 0.2 0.5 ± 0.1
1 *0.006
CfB -0.2 ± 0.2 -0.1 ± 0.2 0 ± 0.2 0 ± 0.2
(%) -32.8 (-50.2, 0.6) -8.1 (-27.5, 26.3) 5 (-22.6, 23.2) -0.9 (-25.5, 53.1)
PTH (pg/ml)
Baseline 90.7 ± 39.5 92.5 ± 46.6 88.1 ± 42.8 94.9 ± 46.6 0.98
Week 12 53.9 ± 34.4
2, 3, 4† 83 ± 40.5
1, 4 87.8 ± 39.8
1, 4 92.9 ± 44.6
1, 2, 3 *0.047
CfB -36.8 ± 60.3 -9.4 ± 58.7 -0.1 ± 63.6 -2 ± 57.2
(%) -57.6 (-70.4, -8.9) -34.8 (-54.6, 88.6) 31.4 (-52.4, 63.7) 16.6 (-43.8, 79.2)
Week 24 35.8 ± 19.1
2, 3, 4†# 68.8 ± 36.9
1, 3, 4 80.8 ± 40
1, 2, 4 97.5 ± 40.5
1, 2, 3 *0.001
CfB -54.9 ± 42 -23.6 ± 54.5 -7.3 ± 41.3 2.6 ± 66.9
(%) -52.4 (-67.8, -28.5) -29.6 (-54.4, 19) -8.9 (-31, 53.9) 9.9 (-41.6, 125.8)
CT(pg/ml)
Baseline 1.6 ± 0.4 1.5 ± 0.4 1.6 ± 0.3 1.6 ± 0.4 0.862
Week 12 12.4 ± 4.7
2, 3, 4† 7.9 ± 4.2
1, 4 † 6.8 ± 2.7
1, 4 † 1.6 ± 0.3
1, 2, 3 *0.001
CfB 10.8 ± 4.8 6.4 ± 4.1 5.2 ± 2.7 0 ± 0.5
(%) 709.5 (557.6, 955.2) 729.3 (426.1, 1114.3) 313.4 (182.2, 474.5) 6.8 (-16.3, 25.2)
Week 24 24 ± 11.8
2, 3, 4 †# 10.2 ± 7
1,4† 8.9 ± 3.4
1, 4† 1.6 ± 0.4
1, 2, 3 *0.001
CfB 22.5 ± 11.8 8.6 ± 6.7 7.2 ± 3.4 0 ± 0.6
(%) 1181.8 (939.1, 2014.6) 838.8 (658, 1217.1) 435.7 (287.1, 546.7) 1.6 (-26.5, 42.7)
Ca
2+ (mg/dl)
Baseline 9.6 ± 0.7 9.5 ± 0.7 9.3 ± 0.7 9.3 ± 0.7 0.503
Week 12 9.3 ± 0.9 9.4 ± 1 9.3 ± 0.8 9.4 ± 0.7 0.963
CfB -0.4 ± 1 -0.2 ± 1.2 0 ± 1.2 0.1 ± 1.2
(%) -3 (-12.4, 4.2) -0.7 (-15.4, 9.2) 0.1 (-7.4, 2.1) 1.3 (-9.4, 15.6)
Week 24 9 ± 0.8 9.1 ± 0.8 9.3 ± 0.7 9.4 ± 0.7 0.483
CfB -0.7 ± 1.1 -0.5 ± 0.8 -0.1 ± 1.1 0.1 ± 1.1
(%) -9.7 (-12.1, 0.3) -7 (-9.5, -3.1) -3.9 (-9.4, 11.2) 4.2 (-10.1, 10.3)
Phosphorus (mg/dl)
Baseline 3.7 ± 0.6 3.8 ± 0.5 3.9 ± 0.7 3.6 ± 0.6 0.489
Week 12 3.6 ± 0.6 3.9 ± 0.6 3.6 ± 0.6 3.7 ± 0.7 0.608
CfB -0.1 ± 1 0.1 ± 0.8 -0.3 ± 0.9 0.2 ± 0.7
(%) -4.2 (-16.3, 26.3) 3.6 (-15.7, 22.2) -7.5 (-20.7, 9.8) 0 (-2.6, 24.1)
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Page 6 of 13response to the E+S intervention (P < 0.05), with a signifi-
cant increase at 12 wks as well as at 24 wks, and femoral
neck BMD at 12 and 24 wk was greater than found in the
other 3 groups (P < 0.05). The other groups showed no
significant improvement in femoral neck BMD with the
intervention, but higher BMD levels were seen in the E
and S groups compared to the control group (P <0 . 0 5 ) .
T h ec h a n g es e e ni nb o t ht h eL 2-L4 BMD and femoral
neck BMD reveals that exercise training and supplementa-
tion had a synergistic effect on the BMD.
Inflammatory markers
Attenuated levels of TNF-a compared to baseline were
observed at weeks 12 and 24 in both the E+S and the S
groups (P < 0.05) such that they decreased from baseline
by 34.1 ± 24.7 and 16.9 ± 33.1 pg.ml
-1, respectively
(Table 3). The decrease was significantly greater in the
E+S group (P < 0.05), and both groups had a greater
decrease than the E and Con group (P < 0.05). The
exercise and N-3 PUFA supplement acted synergistically
to cause the decrease in TNF-a b u ti ta p p e a r st h a tt h e
supplement contributed more so to this decrease.
IL-6 levels did not change at 12 weeks, but a signifi-
cant decrease was observed in the E+S group at 24 wks
(Table 3). The IL-6 levels were lower in the E+S group
than any of the other groups, and E and S groups were
lower than the control group (P < 0.05). PGE2 decreased
at both 12 and 24 wk in the E+S group, but not in the
other groups. This decrease was only significantly
greater than the S and Con group at 12 wk. At 12 wks,
the IL-6 levels were similar between the E+S and E
groups, and both groups were higher than the S and
Con group (P < 0.05). However at 24 wk, all interven-
tion groups showed a decrease in PGE2 levels from
baseline, and all had greater decreases than the Con
group (P < 0.05). The decrease seen in the E+S group
was greater than in either the E (~30%) and S groups
(~32%) (P < 0.05), and they were not different from
each other.
Hormones
Estrogen levels increased from baseline at both 12 and 24
wks in the E+S group but not in any of the other groups
(P < 0.05) (Table 3). Further the E+S group had higher
estrogen levels at these 2 time points than any of the
other groups (P < 0.05). Calcitonin levels demonstrated a
significant increase from baseline at 12 and 24 wks in all
intervention groups (P < 0.05), and the E+S group had a
greater change from baseline than the other 2 interven-
tion groups. At 24 wks all groups still had elevated levels
of CT over baseline (P < 0.05), but only the E+S group
continued to show a significant increase again over the
12 wk measurement (P < 0.05). This resulted in the E+S
group having greater CT levels (24.0 ± 11.8) than either
of the E (10.2 ± 7.0) and S (8.9 ± 3.4) group (P <0 . 0 5 ) .
The Con group (1.6 ± 0.4) demonstrated no change in
the 24 wks.
Concomitantly, PTH showed a decrease in the E+S
group only both at 12 and 24 weeks, while both the E
and S groups showed a non-significant decline. Again
the PTH levels were lower than in either of those inter-
vention groups, which showed no difference from each
other but were lower than the PTH levels in the Con
group (P < 0.05).
At 12 and 24 weeks, osteocalcin and 1, 25 Vit D levels
had increased from baseline (P < 0.05) in the E+S group
and these levels were greater than observed in any of
the other groups (P < 0.05). There were no differences
in osteocalcin levels between the other groups, while 1,
2 5V i tDw a sg r e a t e ri nt h eEa n dSg r o u pt h a ni nt h e
control group (P < 0.05). C-telopepide levels decreased
from baseline only at 24 wks in the E+S group, with no
changes in the other groups. The E+S concentrations of
CTX were only significantly greater than the Con group
(P < 0.05).
Serum ions
Calcium and phosphorus concentration remained stable
through the 24 week intervention in all groups (Table 3).
There were no differences in these levels between and of
these either before or during the intervention.
Correlations
The association between the inflammatory markers and
biomarkers of BMD in all groups are shown in Table 4.
Significant negative correlations were observed between
Table 3 Baseline, Week 12, and 24 Values of Bone Mineral Density, Inflammatory Markers, and Osteoporosis Biomar-
kers in Different Groups of Post-Menopausal Women (Continued)
Week 24 3.2 ± 0.6 3.5 ± 0.6 3.7 ± 0.8 3.6 ± 0.7 0.185
CfB -0.5 ± 0.9 -0.3 ± 1 -0.2 ± 1.2 0.1 ± 0.7
(%) -10.7 (-35.7, 7.6) -15.7 (-23.7, 2.9) 5 (-29, 14.8) 0 (-11.7, 14.1)
E+S = Exercise + Supplement; E = Exercise; S = Supplement; Con = Control; CfB: Change from Baseline.
*: P < 0.05, significant difference between groups.
†: P < 0.05, significantly different from baseline values (within groups, baseline vs. week 12).
#: P < 0.05, significantly different from week 12 values (within groups, week 12 vs. week 24).
Superscripts denote significant differences among the groups (E+S = 1; E = 2; S = 3; and Con = 4).
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Page 7 of 13L2-L4 and femoral neck BMD, estrogen, osteocalcin, and
CT with inflammatory markers TNF-a (r = -0.289; P =
0.002, r = -0.238; P =0 . 0 4 9 ,r = -0.283; P = 0.001, r =
-0.281; P =0 . 0 0 1 ,a n dr = -0.484; P = 0.001, respec-
tively) and PGE2 (r = -0.219; P = 0.005, r = -0.264; P =
0.030, r = -0.223; P = 0.004, r = -0.249; P = 0.001, and
r = -0.424; P = 0.001, respectively) (Table 4). Results
from the mixed model regression showed that for each
unit (pg/ml) decrease in TNF-a concentration there was
an increase of 49.8 g/cm
2, 25.9 g/cm
2, 0.7 pg/ml, 0.7 ng/
ml, and 1.7 pg/ml, respectively, in L2-L4 and femoral
neck BMD, estrogen, osteocalcin, and CT. Additionally
each unit (pg/ml) decrease in PGE2 concentrations
resulted in 8.7 g/cm
2, 6.6 g/cm
2, 0.12 pg/ml, 0.13 ng/ml,
and 0.29 pg/ml increase, respectively, in L2-L4 and
femoral neck BMD, estrogen, osteocalcin, and CT in
these women. However, no significant correlation was
o b s e r v e db e t w e e n1 ,2 5V i tD ,C T X ,P T H ,C a
2+,a n d
phosphorus with either TNF-a or PGE2 (Table 4). PTH
and IL-6 levels were positively correlated (r = 0.216; P =
0.005), while a negative correlation between CT and IL-
6 concentrations (r = -0.169; P = 0.027) was noted. The
mixed model regression showed that each unit decrease
in IL-6 concentration resulted in 0.13 unit decrease in
PTH levels, and each unit decrease in IL-6 concentra-
tion resulted in 0.59 unit increase in CT levels.
PTH and TNF-a and PGE2 levels were not associated
(Table 4).
Fatty acid composition
Neutrophil phospholipids PUFA content is expressed as
a percentage of total phospholipid. Fatty acid content is
presented in Table 5. No significant changes (P > 0.05)
were observed in neutrophil membrane content when
comparing linoleic acid (LA), Arachidonic Acid (AA),
EPA and DHA values in the E and Con groups before
and after the study. Following N-3 PUFA supplementa-
tion, the neutrophil phospholipids content of DHA and
EPA increased significantly (P <0 . 0 5 )i nE + Sa n dS
groups, while the neutrophil phospholipid content of LA
and AA was significantly reduced (P < 0.05) (Table 5).
Discussion
Prior evidence [2,12-32] indicates that both dietary fats
and physical activity can influence bone health and alter
inflammation. This study examined the combined effect
of N-3 PUFA supplementation and exercise on BMD
and inflammatory markers. The novel findings of this
study are: 1) 24 wks of aerobic exercise in combination
with N-3 PUFA supplementation synergistically
increases L2-L4 and femoral neck BMD in healthy post-
menopausal women, 2) inflammatory markers (TNF-a,
IL-6) were attenuated with N-3 PUFA supplementation
alone and exercise+supplementation, and 3) augmenta-
tion of estrogen, osteocalcin and 1, 25 Vit D levels were
s e e na f t e r2 4w kw i t he x e r c i s e+supplementation only.
These findings clearly show that the combination of
PUFA supplementation with aerobic exercise provides
numerous benefits on bone density and inflammation
over exercise alone or supplementation alone. Addition-
ally this study demonstrated that the reductions in
inflammatory markers were related to the increases
observed in BMD.
Although changes in bone turnover are slow, this study
demonstrated that E+S resulted in a 15% increase in
BMD in the L2-L4 region and a 19% increase in the
femoral neck. Slight but non-significant increases in
BMD were seen with exercise alone and with supplemen-
tation alone, but the N-3 PUFA acted synergistically with
the exercise to result in profound changes in BMD in a
Table 4 Correlation of Inflammatory Markers with Bone Mineral Density and Osteoporosis Biomarkers in Healthy Post-
menopausal Women
TNF-a (pg/ml) IL-6 (pg/ml) PGE2 (pg/ml)
Regression Regression Regression
Correlation RC *P < Correlation RC *P < Correlation RC *P <
L2-L4 BMD (g/cm
2) -.289 -49.8 *0.002 -.126 -25.1 0.123 -.219 -8.7 *0.005
Femoral neck BMD (g/cm
2) -0.238 -25.9 *0.049 -.097 -21.3 0.174 -.264 -6.6 *0.030
Estrogen (pg/ml) -.283 -0.7 *0.001 .065 0.30 0.171 -.223 -0.12 *0.004
Osteocalcin (ng/ml) -.281 -0.7 *0.001 -.157 -0.37 0.085 -.249 -0.13 *0.001
1, 25-dihydroxyvitamin D3 (pg/ml) -0.101 -0.1 0.147 -.048 -0.06 0.545 -.123 -0.03 0.103
CTX (ng/ml) 0.143 24.1 0.078 .119 20.9 0.137 .067 2.3 0.405
PTH (pg/ml) 0.109 0.06 0.207 .216 0.13 *0.005 .115 0.01 0.162
CT(pg/ml) -.484 -1.7 *0.001 -.169 -0.59 *0.027 -.424 -0.29 *0.001
Ca
2+ (mg/dl) 0.115 3.3 0.117 .007 0.48 0.850 .113 0.69 0.258
Phosphorus (mg/dl) 0.067 2.9 0.342 .036 1.68 0.596 .172 1.34 0.127
*: P < 0.05, Adjusted for the group through the study based on mixed model.
RC: Regression coefficient
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Page 8 of 1324 week period in this cohort of post-menopausal
women.
Numerous factors may have contributed to these
changes in BMD. All groups except the Con group showed
increased CT and osteocalcin levels after the intervention
period; although these increases were most dramatic in
the E+S group. These findings are similar to those
reported by Alev et al. [27] who found a 54% increase in
CT levels after an aquatic exercise program, while another
study reported 17.1 and 18.3 pg.ml
-1 increases respectively
after endurance and strength exercise program than base-
line (1.2 pg.ml
-1) values [38]. Likewise previous research
has also shown increases in osteocalcin with 12 and 16
weeks of exercise training [22]. These increases in osteo-
calcin concentrations have been observed with exercise
training in both eumenorrheic, pre-menopausal [23] and
post-menopausal women [24]. The underlying mechan-
isms of how exercise training and N-3 PUFA augments
CT and osteocalcin levels are unknown, but these
increases in CT and osteocalcin levels seem to be involved
in increasing osteoblast-mediated bone formation in phy-
siological concentrations and contribute to a more positive
bone balance [12].
In addition to the enhancement of bone formation, our
data has shows a decrease in bone resorption as reflected
by a decrease in serum CTX levels. At 24 wks of the inter-
vention CTX levels had decreased 32% in the E+S group,
and this response seems to be a synergistic effect of the
exercise and N-3 PUFA supplementation as there were no
significant changes in either of these groups. Additionally,
the changes in CTX coincide with the increases in L2-L4
and femoral neck BMD. Previous research has shown that
N-3 PUFAs protect against age-related bone loss. Amy
et al. [15] reported that incorporating walnuts and flaxseed
into the diet to increase a-Linolenic Acid (ALA), and con-
sequently decrease the N-6/N-3 ratio, reduced serum
N-telopeptides (NTx) (a bone resorption marker) and
maintained levels of serum bone-specific alkaline phospha-
tase (BSAP). Likewise animal studies have also shown an
anti-resorptive effect of exercise [39,40]. James et al. [28]
demonstrated that long-term moderate intensity resistance
training in women on hormone therapy, reversed bone
loss, decreased bone turnover, increased femur BMD, and
caused a 9% decrease in CTX. Our findings suggest that
the positive effects of exercise and N-3 PUFA intervention
on bone mass in post-menopausal women may result
from the anti-resorptive properties of either N-3 or exer-
cise training induced by decreasing levels of serum CTX.
Our findings parallel previous reports that endurance
exercise training increases serum 1, 25 Vit D [26,41]
and decreases serum PTH concentrations [41]. With
regard to the effect of exercise on calciotropic hor-
mones, it is accepted that exercise promotes a positive
calcium balance and increases skeletal mass, chiefly as a
result of increased 1, 25 Vit D levels, decreased serum
PTH and enhancement of intestinal calcium absorption
[41].
Additionally research with N-3 PUFAs has demon-
strated a protective effect of long chain N-3 PUFAs on
age-related bone loss due to modulation of local factors
and hormones such as insulin like growth factor I (IGF-1),
PTH, and 1, 25 Vit D [17]. Our recently published data
[12] also demonstrated that N-3 PUFA with and without
weight-bearing exercise training in post-menopausal
women increased CT and decreased PTH concentrations,
indicators of bone formation and resorption, respectively.
Table 5 Fatty acid composition of neutrophil extracts expressed as a percentage of total fatty acid content before and
after dietary supplementation
Variables Groups E+S E S Con P <
18:2§LA
Before 16.7 ± 2.8 17.1 ± 2.4 16.9 ± 3.4 17.2 ± 2.9 0.098
After † 6.9 ± 3.5
2, 4 17.2 ± 2.7
1, 3 † 7.2 ± 3.8
2, 4 16.9 ± 3.1
1, 3 * 0.001
20:4§AA
Before 21.7 ± 6.1 22.2 ± 3.8 22.2 ± 4.3 22.4 ± 5.1 0.121
After † 12.1 ± 4.2
2, 4 22.7 ± 5.9
1, 3 † 11.9 ± 6.2
2, 4 22.8 ± 5.4
1, 3 * 0.001
20:5§EPA
Before 0.3 ± 0.6 0.4 ± 0.6 0.3 ± 05 0.3 ± 0.2 0.446
After † 4.9 ± 1.9
2, 4 0.3 ± 0.2
1, 3 † 4.4 ± 0.4
2, 4 0.4 ± 0.2
1, 3 *0.001
22:6§DHA
Before 1.9 ± 1.8 2.1 ± 1.4 2.0 ± 1.3 2.2 ± 1.2 0.331
After † 4.9 ± 2.8
2, 4 2.0 ± 1.1
1, 3 5.1 ± 1.4
2, 4 † 2.1 ± 1.3
1, 3 *0.001
E+S = Exercise + Supplement; E = Exercise; S = Supplement; Con = Control; LA = Linoleic acid; AA = Arachidonic acid; EPA = Eicosapentaenoic acid; DHA =
Docosahexaenoic acid,
§ Ratios represent number of carbon-carbon double bounds. Superscripts denote significantly differences among the groups (E+S = 1; E = 2; S = 3; and Con = 4).
†P < 0.05, significantly different from baseline values (within groups, baseline vs. week 24).
Values are mean ± SD
Tartibian et al. Nutrition & Metabolism 2011, 8:71
http://www.nutritionandmetabolism.com/content/8/1/71
Page 9 of 13These hormonal changes were greater when supplementa-
tion was accompanied by exercise training. Thus the com-
bined stimulus of aerobic exercise with N-3 PUFA
consumption enhanced bone formation and suppressed
bone resorption, resulting in an increased demand for
minerals that was satisfied by an increase in serum 1, 25
Vit D and increased intestinal absorption of Ca
2+. Possibly
the increased Ca
2+ absorption suppressed serum PTH
levels, and the decreased level of serum PTH in the E+S
group may be related to increased concentration of EPA
and DHA in membrane phospholipids as well as increased
Ca
2+ absorption following N-3 PUFA consumption and
participation in long-term aerobic exercise training.
Bone mineral density has been linked to estrogen levels,
and the estrogen deficiency that occurs with menopause is
tightly linked to low BMD. While exercise and supplemen-
tation alone had no significant effect on estrogen levels, we
observed a 126% increase in estrogen levels in the E+S
group. This agrees with our recent findings that found
increased estrogen levels in post-menopausal women fol-
lowing 16 weeks weight-bearing exercise either alone or
with N-3 PUFA supplementation [12], but is in contrast
with the findings of McTiernan et al.[ 4 2 ]w h or e p o r t e d
reduced estrogen levels following a 12-month moderate-
intensity exercise intervention in post-menopausal
women. Most likely, the increased levels of estrogen in the
present study were affected by coordinated changes in
increased CT and decreased PTH levels that interplayed
to allow the elevations in estrogen levels. According to
previous investigations [43], when estrogen is withdrawn,
such as after menopause, the rate of bone resorption is
increased. Estrogen’s major effect on bone tissue, there-
fore, may be to inhibit bone resorption rather than to pro-
mote bone formation. This anti-resorptive effect is
mediated by the estrogen-induced synthesis and release of
paracrine factors from osteoblast cells, which then control
osteoclastic activity [43]. Estrogen increases the release of
transforming growth factor-b (TGF-b) from osteoblasts,
which subsequently inhibits activity of osteoclasts [44].
IL-6, a cytokine that increases osteoclastic activity, is regu-
lated by estrogen, as IL-6 release from osteoblasts has
been shown to be inhibited by estrogen. Further evidence
of the anti-resorptive effect of estrogen is provided by
observations of increased synthesis of IL-6 and increased
osteoclastic cell number in estrogen-deficient women [45].
Estrogen not only affects bone metabolism at the cellular
level but also has indirect effects systemically. Estrogen
interacts with many other hormones, including CT and
PGs, which result in a response of bone tissue. When the
body is in a state of hypercalcemia, the C-cells are stimu-
lated to release CT [45], which inhibits bone resorption.
CT seems to be influenced by estrogen, as higher levels of
estrogen have been strongly correlated with CT secretory
capacity [46]. There is little known about the interaction
between estrogen and PTH. Although estrogen does not
affect PTH secretion, estrogen does seem to have an indir-
ect effect on PTH action on bone. It has been suggested
that estrogen inhibits bone cell responsiveness to PTH,
thus reducing bone resorption [45]. This indirect effect
further explains why estrogen withdrawal results in
increased bone resorption.
The immunosuppressive effects of the either moderate
intensity exercise training [47] or N-3 PUFAs [48-51] have
been reported previously. Recently we showed that inges-
tion of N-3 PUFAs can be effective in ameliorating,
eccentric exercise-induced, inflammatory markers includ-
ing IL-6, PGE2 and TNF-a [51]. Previous studies [52] also
revealed that reducing the consumption of fat calories
from 36% to 27% with low fish-derived N-3 PUFA resulted
in increased levels of IL-1b,a n dT N F - a production by
peripheral blood mononuclear (PBMN) cells stimulated
with lipopolysaccharide (LPS) while the same low fat diet
with high fish-derived N-3 PUFA led to lowered amounts
of these cytokines produced. Thus, decreased levels of IL-
6, TNF-a and PGE2 in the present study can be explained
by immunosuppressive effects of the either moderate
intensity aerobic exercise training or N-3 PUFA. On the
basis of previous studies, IL-6 possesses both pro-and
anti-inflammatory actions [53]. The overproduction of
pro-inflammatory IL-6 has been associated with multiple
organ-system dysfunction and mortality. In contrast,
immunoregulatory function of anti-inflammatory IL-6
inhibits the production of several pro-inflammatory cyto-
kines including IL-6 and TNF-a by altering the accessory
cell function of macrophages [54]. Generally following
exercise, pro-inflammatory cytokine levels are counterba-
lanced by anti-inflammatory cytokine levels promoting
homeostasis; however if levels are unrestrained, post exer-
cise infection may occur [55]. Hence it is possible that the
decreased levels of IL-6 (~40%) and TNF-a (~80%)
observed with the E+S and S interventions may be related
to immunoregulatory function of anti-inflammatory IL-6.
Likewise, since PTH regulates the circulating levels of the
inflammatory cytokines IL-6 and TNF-a [56], we reasoned
that in the present study aerobic exercise and N-3 PUFA
consumption, by suppressing PTH production, might also
decrease the serum IL-6 and TNF-a levels.
Paralleling the postmenopausal bone loss, increased pro-
duction of cytokines is a possible mechanism that contri-
butes to post-menopausal bone loss [57]. Cytokines play
both a direct and an indirect role in the regulation of
osteoclast and osteoblast activities [58]; therefore, a
decrease in cytokine production may be beneficial to
BMD. Consistent with our findings, a recent study has
suggested that bone loss in post-menopausal women is
mediated by increased production of cytokines such as IL-
1, IL-6, IL-8 and TNF-a [59], and our data support this.
Inflammatory processes can up-regulate many cytokines,
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Page 10 of 13such as IL-1, IL-6 and TNF-a, which strongly stimulate
CRP production from the liver [60,61] as well as inducing
bone resorption [7,9,62]; and increased bone resorption
may result in increased bone turnover and decreased
BMD. In support of this hypothesis, the production of
IL-1, IL-6 and/or TNF-a by peripheral blood monocytes
was positively correlated with bone resorption or spinal
bone loss in healthy pre- [63] and post-menopausal [64]
women, and serum IL-6 concentrations predicted femoral
bone loss in healthy post-menopausal women [65]. Also,
increased levels of PGs, especially PGE2 (known to be
potent activators of bone remodeling) are found in several
disorders characterized by chronic inflammation [66].
Data from supplement studies in the elderly indicate
that N-3 PUFA intakes may promote bone mineral main-
tenance in this population [67]. Eighteen-month of EPA
and g-linolenic acid supplementation in elderly post-
menopausal women revealed that BMD at the lumbar
spine was maintained and BMD of the femoral neck was
increased [67]. In a cohort of growing rats fed on a semi-
synthetic diet supplemented with tuna oil, Kruger and
Schollum [68] found that DHA concentrations in red
blood cell membranes were associated with BMD, and
with calcium absorption in bone. Likewise, Weiler and
Fitzpatrick-Wong [69] found that higher concentrations of
plasma DHA were associated with an attenuated bone
resorption in piglets fed on diets containing different ratios
of N-6 to N-3 fatty acids. An increased consumption of
N-3 PUFA decreases the AA:EPA ratio, PGE2 concentra-
tion, and release from bone. This cascade of effects is
potentially important, as PGE2 has been reported to stimu-
late bone resorption [70]. EPA serves as a precursor for
the formation of PGE3, which also can stimulate bone
resorption. However, the conversion of EPA to PGE3 is
much less efficient than is the conversion of AA to PGE2
[71]. Although measurements of bone PGs were not taken
in the present study, the neutrophil phospholipids PUFA
content results showed that EPA and DHA in the cell
membranes of neutrophils were significantly greater in the
E+S (4.9% and 4.4%, respectively) and S (4.9% and 5.1%,
respectively) groups than in either the E or the Con
groups, while AA and LA were significantly reduced. It is
possible that this shift in fatty acid synthesis decreased
production of PGE2 within the bone while having minimal
effect on PGE3 formation. Therefore, a decrease in cyto-
kines and PGE2 production by long-term aerobic exercise
and cyclooxygenase (COX)-2 inhibitor N-3 PUFAs in the
present investigation can be attributed to increased bone
health measured by L2-L4 and femoral neck BMD.
Our results also support the hypothesis that the ele-
vated L2-L4 and femoral neck BMD, estrogen, osteocal-
cin, and CT experienced during aerobic exercise and N-3
PUFA consumption in healthy post-menopausal women
are negatively associated with the serum inflammatory
markers TNF-a and PGE2. Likewise, elevated CT and
decreased PTH levels during the study period are asso-
ciated (negatively and positively, respectively) with serum
IL-6. These changes in inflammatory indices following
long-term aerobic exercise training and N-3 PUFA sup-
plementation may contribute significantly to the inverse
relationship between inflammatory markers and osteo-
porosis. Together these findings allows the speculation
that increased L2-L4 and femoral neck BMD measures
following exercise training and N-3 PUFA consumption
may be related to increased levels of estrogen, osteocal-
cin, and CT as well as decreased PTH, IL-6, TNF-a and
PGE2 levels in post-menopausal women. In rodent mod-
els, IL-6 mediated stimulation of osteoclast activity and
regulation in the presence of estrogen depletion has been
well reported [72,73]. In the present study, lack of asso-
ciation between serum IL-6 and other variables (with the
exception of CT and PTH) following exercise and N-3
PUFA intervention can be attributed to the elevated
estrogen levels to some extent.
In conclusion, aerobic exercise training plus N-3 PUFA
supplementation was effective in reducing chronic inflam-
mation and increasing BMD in postmenopausal women.
These changes in inflammatory markers are related to
indices that favour enhancement of BMD in healthy
sedentary post-menopausal women. Further studies on the
physiologic effects of N-3 PUFAs and exercise training on
bone metabolism and bone quality to prevent or treat
osteoporosis are needed.
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ELISA: Enzyme-linked immunosorbent assay; RIA: Radioimmunoassay; ANOVA:
Analysis of variance; LA: Linoleic acid; AA: Arachidonic acid; ALA: α-Linolenic
Acid; NTx: N-telopeptides; BSAP: Bone-specific alkaline phosphatase; IGF-1:
Insulin like growing factor I; TGF-b: Transforming growth factor-b; PBMN:
Peripheral blood mononuclear cells; LPS: Lipopolysaccharide; GLA: γ-linolenic
acid; COX: Cyclooxygenase; BMI: Body mass index; VO2max: Maximal oxygen
uptake.
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